The most recent coronavirus SARS-CoV-2 was identified in Wuhan, China in December 2019. The disease is highly pathogenic, invading the world and causing a global pandemic. The world works hard to develop and produce antiviral drugs and vaccines to stop/prevent the disease. SARS-CoV-encoded cysteine protease- papain-like protease (PLpro) is an attractive antiviral drug target. This enzyme plays an important role in the innate immune response to viral infection and is therefore an important molecule to target in the design for an antiviral drug. VIR250 is a potent inhibitor with high selectivity for SARS-CoV-2 PLpro as it involves strong hydrogen bonds, hydrophobic pockets, network of VDW interactions and covalent bond. In this 3-D design you can orientate your way around SARS-CoV-2 PLpro and inhibitor VIR250. Important residues have been coloured and explained through annotations.
Comments